TY - JOUR
T1 - Hybrid (COPP/ABV) therapy in childhood hodgkin's disease
T2 - A study of 53 cases during 1989-1993 at the cancer institute, madras
AU - Sripada, Prasad V.S.S.
AU - Tenali, Sagar G.
AU - Vasudevan, Maitreyan
AU - Viswanadhan, Shanta
AU - Sriraman, Devarajan
AU - Kandasamy, Ravichandran
PY - 1995/1/1
Y1 - 1995/1/1
N2 - The optimal therapy for children with Hodgkin 's disease is controversial. Between 1989 and 1993, 53 children under 14 years of age with Hodgkin's disease were treated with COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin, vinblastine) hybrid chemotherapy. The results were analyzed with the Kaplan-Meier product limit method for survival and the Logrank test for predicting statistical significance. Ten patients (18.87% had early-stage disease (I to IIA) and 43 (81.13% had advanced disease. Lymphocyte-predominant histology was seen in 20 (37.5% patients, nodular sclerosis in 8 (15% mixed cellularity in 21 (39.6% and lymphocyte depletion in 4 (7.56% The male: female ratio was 3.82:1. Complete responses were seen in 51 (96.22% patients, with 47 (92.15% of them in sustained first remission. The event-free survival rate is 90.3% to date. COPP/ABV hybrid chemotherapy is an effective primary therapy for all stages of Hodgkin's disease in children.
AB - The optimal therapy for children with Hodgkin 's disease is controversial. Between 1989 and 1993, 53 children under 14 years of age with Hodgkin's disease were treated with COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin, vinblastine) hybrid chemotherapy. The results were analyzed with the Kaplan-Meier product limit method for survival and the Logrank test for predicting statistical significance. Ten patients (18.87% had early-stage disease (I to IIA) and 43 (81.13% had advanced disease. Lymphocyte-predominant histology was seen in 20 (37.5% patients, nodular sclerosis in 8 (15% mixed cellularity in 21 (39.6% and lymphocyte depletion in 4 (7.56% The male: female ratio was 3.82:1. Complete responses were seen in 51 (96.22% patients, with 47 (92.15% of them in sustained first remission. The event-free survival rate is 90.3% to date. COPP/ABV hybrid chemotherapy is an effective primary therapy for all stages of Hodgkin's disease in children.
KW - Childhood Hodgkin's disease
KW - Hybrid chemotherapy
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0029091308&partnerID=8YFLogxK
U2 - 10.3109/08880019509029583
DO - 10.3109/08880019509029583
M3 - Article
C2 - 7577385
AN - SCOPUS:0029091308
VL - 12
SP - 333
EP - 341
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
SN - 0888-0018
IS - 4
ER -